IL110289A - תכשירי רוקחות המכילים '4-יודו-'4- דאוקסידוקסורוביצין לטיפול באמילואידוזיס - Google Patents
תכשירי רוקחות המכילים '4-יודו-'4- דאוקסידוקסורוביצין לטיפול באמילואידוזיסInfo
- Publication number
- IL110289A IL110289A IL110289A IL11028994A IL110289A IL 110289 A IL110289 A IL 110289A IL 110289 A IL110289 A IL 110289A IL 11028994 A IL11028994 A IL 11028994A IL 110289 A IL110289 A IL 110289A
- Authority
- IL
- Israel
- Prior art keywords
- idx
- iodo
- deoxydoxorubicin
- amyloidosis
- patient
- Prior art date
Links
- 206010002022 amyloidosis Diseases 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 102000001049 Amyloid Human genes 0.000 description 7
- 108010094108 Amyloid Proteins 0.000 description 7
- 208000037259 Amyloid Plaque Diseases 0.000 description 7
- 201000001474 proteinuria Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 description 3
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 108700028909 Serum Amyloid A Proteins 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000004451 qualitative analysis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- 206010059047 Amyloidoma Diseases 0.000 description 2
- 241000984642 Cura Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 101710163305 Fibril protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 101710186630 Insulin-1 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003361 heart septum Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT93MI001800A IT1265055B1 (it) | 1993-08-06 | 1993-08-06 | Uso della 4'-desossi-4'-iododoxorubicina per il trattamento della al amiloidosi |
| ITMI940621A IT1274032B (it) | 1994-03-31 | 1994-03-31 | Uso della 4'-desossi-4'-idodoxorubicina per il trattamento della al amiloidosi nella malattia di alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL110289A0 IL110289A0 (en) | 1994-10-21 |
| IL110289A true IL110289A (he) | 1998-01-04 |
Family
ID=26331037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL110289A IL110289A (he) | 1993-08-06 | 1994-07-12 | תכשירי רוקחות המכילים '4-יודו-'4- דאוקסידוקסורוביצין לטיפול באמילואידוזיס |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5637572A (he) |
| EP (1) | EP0663832B1 (he) |
| JP (1) | JPH08505401A (he) |
| KR (1) | KR100270465B1 (he) |
| AT (1) | ATE200624T1 (he) |
| AU (1) | AU687432B2 (he) |
| CA (1) | CA2142349A1 (he) |
| DE (1) | DE69427116T2 (he) |
| DK (1) | DK0663832T3 (he) |
| ES (1) | ES2157984T3 (he) |
| GR (1) | GR3036221T3 (he) |
| HU (1) | HU217546B (he) |
| IL (1) | IL110289A (he) |
| MY (1) | MY111755A (he) |
| PL (1) | PL180000B1 (he) |
| PT (1) | PT663832E (he) |
| RU (1) | RU2155589C2 (he) |
| UA (1) | UA29461C2 (he) |
| WO (1) | WO1995004538A1 (he) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9418260D0 (en) * | 1994-09-09 | 1994-10-26 | Erba Carlo Spa | Anthracycline derivatives |
| GB9516349D0 (en) * | 1995-08-09 | 1995-10-11 | Pharmacia Spa | Aza-anthracyclinone derivatives |
| US6001331A (en) * | 1996-01-24 | 1999-12-14 | Warner-Lambert Company | Method of imaging amyloid deposits |
| GB9805082D0 (en) | 1998-03-10 | 1998-05-06 | Pharmacia & Upjohn Spa | Heterocyclyl anthracyclinone derivatives |
| GB9805080D0 (en) | 1998-03-10 | 1998-05-06 | Pharmacia & Upjohn Spa | Amino anthracyclinone derivatives |
| PL237739B1 (pl) | 2018-06-06 | 2021-05-17 | Univ Gdanski | Genisteina do zastosowania do leczenia choroby Alzheimera |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4438105A (en) * | 1982-04-19 | 1984-03-20 | Farmaitalia Carlo Erba S.P.A | 4'-Iododerivatives of anthracycline glycosides |
| GB8701381D0 (en) * | 1987-01-22 | 1987-02-25 | Erba Farmitalia | Antitumor agent |
| EP0464206A4 (en) * | 1989-03-24 | 1992-05-13 | Daiichi Pharmaceutical Co., Ltd. | Drug for improving brain function |
| GB2238540B (en) * | 1989-11-29 | 1993-09-29 | Erba Carlo Spa | 13-deoxy-4'-deoxy-4'-iodoanthracyclines |
| JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| NZ241606A (en) * | 1991-02-28 | 1994-08-26 | Iaf Biochem Int | Heteroanthracycline antitumor analogs, preparation and pharmaceutical compositions thereof; intermediates therefor |
| JP4142304B2 (ja) * | 2001-10-22 | 2008-09-03 | 株式会社安川電機 | アーク溶接用ロボット |
-
1994
- 1994-07-12 IL IL110289A patent/IL110289A/he not_active IP Right Cessation
- 1994-07-29 JP JP7506199A patent/JPH08505401A/ja not_active Ceased
- 1994-07-29 DK DK94924299T patent/DK0663832T3/da active
- 1994-07-29 DE DE69427116T patent/DE69427116T2/de not_active Expired - Lifetime
- 1994-07-29 ES ES94924299T patent/ES2157984T3/es not_active Expired - Lifetime
- 1994-07-29 EP EP94924299A patent/EP0663832B1/en not_active Expired - Lifetime
- 1994-07-29 US US08/397,248 patent/US5637572A/en not_active Expired - Lifetime
- 1994-07-29 CA CA002142349A patent/CA2142349A1/en not_active Abandoned
- 1994-07-29 KR KR1019950701284A patent/KR100270465B1/ko not_active Expired - Lifetime
- 1994-07-29 AT AT94924299T patent/ATE200624T1/de active
- 1994-07-29 AU AU74608/94A patent/AU687432B2/en not_active Expired
- 1994-07-29 PT PT94924299T patent/PT663832E/pt unknown
- 1994-07-29 PL PL94308245A patent/PL180000B1/pl unknown
- 1994-07-29 WO PCT/EP1994/002511 patent/WO1995004538A1/en not_active Ceased
- 1994-07-29 UA UA95058382A patent/UA29461C2/uk unknown
- 1994-07-29 HU HU9500375A patent/HU217546B/hu unknown
- 1994-07-29 RU RU95112520/14A patent/RU2155589C2/ru active
- 1994-08-04 MY MYPI94002036A patent/MY111755A/en unknown
-
2001
- 2001-07-13 GR GR20010401072T patent/GR3036221T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2157984T3 (es) | 2001-09-01 |
| WO1995004538A1 (en) | 1995-02-16 |
| JPH08505401A (ja) | 1996-06-11 |
| US5637572A (en) | 1997-06-10 |
| UA29461C2 (uk) | 2000-11-15 |
| DE69427116D1 (de) | 2001-05-23 |
| MY111755A (en) | 2000-12-30 |
| HUT70521A (en) | 1995-10-30 |
| DE69427116T2 (de) | 2001-08-02 |
| EP0663832A1 (en) | 1995-07-26 |
| IL110289A0 (en) | 1994-10-21 |
| HU217546B (hu) | 2000-02-28 |
| ATE200624T1 (de) | 2001-05-15 |
| KR100270465B1 (ko) | 2000-11-01 |
| PT663832E (pt) | 2001-09-28 |
| CA2142349A1 (en) | 1995-02-16 |
| HK1011280A1 (en) | 1999-07-09 |
| PL180000B1 (en) | 2000-11-30 |
| DK0663832T3 (da) | 2001-05-07 |
| GR3036221T3 (en) | 2001-10-31 |
| EP0663832B1 (en) | 2001-04-18 |
| AU687432B2 (en) | 1998-02-26 |
| AU7460894A (en) | 1995-02-28 |
| RU2155589C2 (ru) | 2000-09-10 |
| PL308245A1 (en) | 1995-07-24 |
| HU9500375D0 (en) | 1995-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3835811B2 (ja) | ホスファターゼ又はその誘導体を含む製薬学的組成物 | |
| Meltzer et al. | Cryoglobulinemia—a clinical and laboratory study: II. Cryoglobulins with rheumatoid factor activity | |
| Gianni et al. | New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin | |
| EP0714405B1 (en) | Therapeutic and diagnostic agents for amyloidosis | |
| Behr et al. | Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion | |
| BATEMAN et al. | Fatal complications of intensive antibiotic therapy in patients with neoplastic disease | |
| US20030190319A1 (en) | Antibodies specific for CD44v6 | |
| Moolten et al. | Antitumor effects of antibody-diphtheria toxin conjugates: Use of hapten-coated tumor cells as an antigenic target | |
| MXPA03010035A (es) | Tratamiento y diagnostico de enfermedades mediadas por macrofagos. | |
| US5637572A (en) | Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis | |
| Vaidyanathan et al. | Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate | |
| JPH10506398A (ja) | 炎症性疾患治療用コンジュゲート | |
| US6028060A (en) | Treatment of chronic inflammatory diseases with CM101/GBS toxin | |
| Donald et al. | CURRENT CONCEPTS OE CUTANEOUS PORPHYRIA AND ITS TREATMENT WITH PARTICULAR REEERENCE TO THE USE OF SODIUM CALCIUMEDETATE | |
| HK1011280B (en) | Use of 4'-iodo-4'-deoxydoxorubicin for the treatment of amyloidosis | |
| EP0972032A2 (en) | Peptides for the treatment of systemic lupus erythematosus | |
| Cunningham et al. | Development of a radioimmunoassay for neurone specific enolase (NSE) and its application in the study of patients receiving intra hepatic arterial streptozotocin and floxuridine | |
| Boström et al. | Case of chondrosarcoma with pulmonary and skeletal metastases after hemipelvectomy, successfully treated with 35S-sulfate | |
| Hutson et al. | Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. | |
| Kolarić et al. | Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients: a phase II study | |
| Bajetta et al. | A feasibility study using polychemotherapy (cisplatin+ vindesine+ dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma | |
| Rokosova et al. | Biosynthesis of aortic collagen and glycosaminoglycan following immunological injury | |
| EP0406363B1 (en) | Method to diagnose amyloidoses specifically and substance therefor | |
| GB2223578A (en) | Diagnosis and treatment of amyloidosis using a radiolabelled protein | |
| Shafiroff et al. | Subcutaneous administration of combined fat emulsion with hyaluronidase. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |